Navigation Links
Accuri Cytometers Completes $13 Million Series C Financing
Date:7/8/2008

the Accuri system's easy-to-use analysis software, a critical component of the approach. Accuri's innovations, coupled with its state of the art components, result in a cytometer that is powerful, robust, compact and affordable, at less than one-third the cost of the market leader.

"We are enthusiastic about our investment in Accuri," said Bahaa Fam, Venture Partner, Fidelity Biosciences. "By making flow cytometry technology more affordable, accessible and usable, Accuri's high performance systems have the potential to accelerate and broaden the scope of biomedical research. We welcome this opportunity to help the company progress to the next level."

"Flow cytometry is an essential tool in biomedical research, and Accuri's outstanding team has responded to the need for accessible, affordable easy-to- use systems by completely re-inventing the flow cytometer from the ground up," said Harry Wilcox, Partner at Flagship Ventures. "The Accuri Flow Cytometer System is already gaining traction among researchers, and we are very optimistic about the future potential of this promising company."

"As Accuri continues to commercialize its revolutionary technology, we are very pleased to welcome Fidelity and Flagship representatives as new investors and as Board members," said Pete Shagory, Accuri Chairman and a Partner at Baird Venture Partners. "Their expertise in the research tools space will be especially valuable as Accuri expands its efforts to effectively grow the business."

About Accuri Cytometers

Accuri Cytometers, Inc. is an Ann Arbor-based life sciences company developing and marketing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer(R) is a full featured bench-top cell and bead analysis system that provides similar capabilities to those of industry-lead
'/>"/>

SOURCE Accuri Cytometers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
3. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
4. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
5. Boston Scientific Completes Acquisition of CryoCor
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
8. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
9. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
10. China-Biotics, Inc. Completes Foundation for Its New Plant
11. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Sapphire Energy, Inc. , a global leader ... biotechnology veteran James Levine as president, CEO ... Cynthia ,CJ, Warner, who is stepping down from her ... company,s board of directors. "The impact of ... scale algae-based fuels has been tremendous, from overseeing the ...
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
... I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... 2010 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the LifeTech ... at 2:00 p.m. Eastern.  The conference will take place ... presentation will not be webcast, investors can access the ...
Cached Biology Technology:HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Cardium to Present at the LifeTech Capital Miami Medical Investors Conference 2
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
(Date:7/28/2014)... to map social connections in prairie dogs have ... light on prairie dog communities that may help ... future conservation efforts. The work was done by ... National Evolutionary Synthesis Center (NESCent). , "Prairie dogs ... plague," says Dr. Jennifer Verdolin, lead author of ...
(Date:7/27/2014)... species of mayfly in the southern Western Ghats, a mountain ... is the first time that any mayfly belonging to the ... , The new species, called Labiobaetis soldani , "is ... contribution to the understanding of the Ephemeroptera of Palaearctic and ... describes the new mayfly in the Journal of Insect ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Social network research may boost prairie dog conservation efforts 2
... combination of the biology of marine mammals, mechanical vibrations ... scientists to better understand the potential harmful effects of ... An international team of researchers from UC ... Zoo in Sweden has developed an approach that integrates ...
... 31, 2010 − A York University doctoral student who discovered ... lab one morning has completed a study that examines 84 ... including the one Jason Gibbs found in downtown Toronto ... identified or described before. Gibbs, expansive study will help ...
... brains, mouth bacteria behaving badly and the hundreds of ... some of the highlights at the Society for General ... annual event takes place on 6-9 September at the ... experts will present cutting-edge scientific research covering a wide ...
Cached Biology News:Researchers develop simulation to better understand the effects of sound on marine life 2Researchers develop simulation to better understand the effects of sound on marine life 3York U researcher finds new bee in downtown Toronto 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... 220-240 V, uses floating pin printing technology ... and other biomolecules onto a variety of ... generate high-density arrays with greater than 80,000 ... 57,000 spots per membrane with a capacity ...
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: